½Ã±Ð¸ê®Æ 2024.07.01­×­q
¥»°|¦å²G³zªR±wªÌ¶·ª¾
¦å²G³zªR¶¼­¹­ì«h
¦åºÞ³q¸ô±M°Ï
»{ÃÑB«¬»PC«¬¨xª¢
ºC©ÊµÇŦ¯f¶¼­¹­ì«h
¥~Äy¬ÝÅ@½Ã±Ð¸ê®Æ
¤¤¬î¨Î¸`,¦Y-´N¬O³o»ò²³æ
¦å¹[±±¨î±M°Ï
ªÍµ²®Ö-½Ã±Ð³æ±i
«D®Ö®a¶é
Á¤¤ß¤ñ¤ß-­°§C³zªRὺޯkµh±M°Ï
 
¥»°|¦å²G³zªR±wªÌ¶·ª¾ (¤B¤ZµX¡A¦å²G³zªR«Ç¡A¤å³¹¨Ó·½¡GµL¡A2019/02/12§ó·s)

¤@¡B´_°·¤j¼Ó¦å²G³zªR«Ç¦³¤T°Ï¡]6A¡B6B¡B7H°Ï¡^

¡]¤@¡^±Æµ{®É¶¡¬°¡G
1.¦­¯Z¡£A¡¤7:50¢w12:10
2.¤¤¯Z¡£B¡¤13:00¢w17:20
3.±ß¯Z¡£C¡¤18:00¢w22:20
³ÆµùA.¹O®É·|¼vÅT¤U¤@¯ZµÇ¤Í¤W°w®É¶¡­Y¦]­Ó¤H²z¥Ñ¡A±NÁYµu±zªº³zªRªvÀø ®É¶¡¡CB.¥¼©T©w§É¦ìªÌ¡A½Ð¦Ü®aÄݵ¥­Ô«Ç¤½§GÄæ¬d¬Ý§É¦ì¡A¤u§@¤H­û·|¹w¥ý·Ç³Æ§É¸n¡B´Ö³Q¤ÎªEÀY¡BªE®M¡A­Yº|±¼ªÌ½Ð¦Ü¹q¸£«Ç§iª¾¤u§@¤H­û¡A¦A¬°§A·Ç³Æ¤@®M¡F¤w³W«h³zªR¯f¤H¡A¨Ì³QªA²Õ³W©w·|¤À°t±MÄݪº¸mª«Âd¡C

¡·¦å²G³zªR«Ç³X«È¶·ª¾
      ºÞ¨î®É¶¡¡G¤W¤È 09¡G00-12¡G30                
       ¤U¤È 14¡G00-17¡G30
       ±ß¤W 19¡G00-21¡G00
    ³ÆµùC.ºÞ¨î®É¶¡¤º»Ý¶i¤J³zªR«Ç
           1.½Ð«öªù¤f®Çªº«ö¹a¡C2.§iª¾±ý«ô³X¤§µÇ¤Í»P§É¸¹¤Î©Ò¦bªº³zªR°Ï°ì¡C
3.¤Å´c·N¯}Ãa¦Û°Êªù®°¡C4.³Xµø«e«á»Ý¬~¤â¡C
      ³ÆµùD.¤U¦C¤H­û¤£¥i¶i¤J¡G 1.12·³¥H¤U¨àµ£¡C2.±w¦³µo¿N©Î¨ä¥L¶Ç¬V¯f¡C
3.«DªvÀø¬ÛÃö¤§¤H­û¡C

¡]¤G¡^ª`·N¨Æ¶µ:

1.³zªR«e·Ç³Æ¤u§@¡G

¡]1¡^±N¥´°w³¡¦ì²M¼ä°®²b¡C
¡]2¡^µÛ»´«KªA¸Ë¶qÅé­«¡C
¡]3¡^¨Æ¥ý³Æ§´­Ó¤Hª««~¡A¨Ò¦p¡G¶}¤ô¡B¦B¶ô¡B¤î¦å±aµ¥¡C

2.ªvÀø­û¥´°w¥H³ø¨ì¤§¥ý«á¶¶§Ç¬°­ì«h¡C

3.³zªR¤¤¦p¦³¤£¾A¯gª¬¡A¨Ò¦p¡GÀY·w¡B¹Ã¦R¡B©âµ¬¡B«_§N¦½…..µ¥½Ð¥ß¨è¦VªvÀø®v¤ÏÀ³¡C

4.½Ð¦@¦PºûÅ@¥»³æ¦ìÀô¹Ò¡A¦UÃþ¤½ª«¥Î²¦½Ð°È¥²Âk¦ì¡A½ü´È½Ð¾ã»ô¦¬¦n¸m©ñ¦b¦U¦Û³zªR§É«e¡]¬°ÁקK¤u¦w°k¥Í¡A½Ð¤ÅÀH·N©ñ¸m³q¹D©Î¼Ó±è¥X¤J¤f¡^¡C

5.­ì«h¤W¨C¤ë¤ëªì¬P´Á¤T¡B¥|¬°©â¦åÀËÅç¤é¡A¹J°ê©w¨Ò°²¤é«h¦³Åܧó¡A½ÐµÇ¤Í°t¦X¡A¦A¦¸»P¤u§@¤H­û½T»{¤é´Á¡A¤ÅµL¬G¯Ê®u¡C

6.©â¦å¤é¡G ¦]¶i­¹«á©â¦å·|¼vÅT¬Y¨ÇÀËÅç­È¡A¬°½T«OÀËÅçµ²ªGªº·Ç½T«×¡A½Ð©â§¹¦å«á¦A¶i­¹¡£¥i¯àªº¸Ü¡A¦ý¤£«j±j¡¤¡A©â¦å¹j¶g¶g¤@¡B¶g¤GÅç¦å³ø§i¥X¨Ó¡AÂå®v·|¬d©Ð¬Ý³ø§i¡AµøÀËÅçµ²ªG½Õ¾ã³zªRªvÀø³B¤è¤ÎÃĪ«¡C

7.µÇŦ¬ì±`³W¥ÎÃÄ¡A¨C¤ë¤À°Ï¶}¥ß¡A¨C¦¸28¤Ñ¥÷(·P«_ÃÄ°£¥~)¡A½Ð¨ÌÂåÅñ«ö®ÉªAÃÄ¡A¦p¦³³Ñ¾lÃĪ«½Ð§iª¾ªvÀø®v¡C

¤G¡BÅTÀ³Àô«O¹B°Ê¡G

¡]¤@¡^¦Û³Æ¶¼¤ôªM¡BÀ\¨ã

¡]¤G¡^°t¦X©U§£¤ÀÃþ¡G

1.·P¬V©Ê©U§£:©Ò¦³ªg¨ì¦å²G¤Î®ø¬rÃĤôªºªF¦è¡A¤@«ß¥á¤J¡£¬õ¦â³U¡¤©U§£±í¡C
2.«D·P¬V©Ê©U§£:¤@¯ë©Ê©U§£¦p½Ã¥Í¯È¡B¶ì½¦³Uµ¥¤@«ß¥á¤J¡£¥Õ¦â³U¡¤©U§£±í¡C
3.¼p¾l¦^¦¬±í¡G³]©ó¦^¦¬«Ç¡C


¤T¡B°t¦X¥þ¥Á°·«O¤§³zªR¥Ó³ø§@·~¡A½Ð±N°·«OIC¥d¥æµ¹ªvÀø­û¡A¥¼±a°·«OIC¥dªÌ¡A·í¤é³zªR»Ý¦Û¶O¡A¥B¤£±o»â¨úE P O¡BÅK¾¯µ¥±`³ÆÃÄ¡C

¥|¡B½Ð¾¨¶q¤£­n½Õ¯Z©Î½Ð°²¡C­Y­n½Ð°²½Ð¾¨¦­´£¥X¡A¦³ªÅ¦ì±N¾¨¶q°t¦X½Õ¯Z¡C

¡]¤@¡^½Õ¯Z­ì«h¡G
1.¦­¯Z¡£A¡¤«e¤@¤Ñ´£¥X¡A½Ð¼·7317123Âà¤À¾÷2770¡B2771§iª¾¨k§Þ³N®v©Î·í¯Z°Æ²Õªø¡C
2.¤¤¯Z¡£B¡¤·í¤Ñ¦­¤W¤QÂI«e
3.±ß¯Z¡£C¡¤·í¤Ñ¤U¤È¥|ÂI«e
¡]¤G¡^¹J³{¦~¹L¸`¤§½Õ¯Z¥H«e¤@¯Z´£¥X¡A¦]¦h¼ÆµÇ¤Í¬Ò¥X°|¡C
¡]¤T¡^µÇ¤Í­Y¥~°|±¾«æ¶E©Î¦í°|³zªR¡A½Ð®aÄݳqª¾³zªR«Ç¡A¥~°|¥X°|®É½Ð¨Ó¹q¡]2770.2771¡^³qª¾³zªR«Ç¬°±z«ì´_§É¦ì¡C

¤­¡B¤½¦@¦w¥þ¡G

¡]¤@¡^½T«O¤½¦@¦w¥þ¡A½ÐµÇ¤Í¤Î®aÄÝ¿í¦u¡yÄY¸T§l·Ï¡A¨Ã¼ôª¾¥»³æ¦ì¦w¥þ°k¥Í³]³Æ¡z¡C
¡]¤G¡^³zªR¹Lµ{¦p¦³­«¤j¨a®`µo¥Í®É¡A½ÐµÇ¤Í¤Î®aÄÝ¿í·ÓÂåÅ@¤H­ûªº«ü¥Ü©¹¦w¥þªù²¨´²¡AÂí©w¦]À³¡C
¡]¤T¡^¨p¤Hª««~½Ð¦Û¦æ«OºÞ¡A³zªR«Ç¤£­t³d«OºÞ³d¥ô¡C

¤»¡B¦pªG§É¦ì¤w¸g©T©wªºµÇ¤Í¡A½Ð¼ô°O¦Û¤vªº°Ï°ì¤Î§É¸¹¡A¥H«K¤u§@¤H­ûªº§@·~¡C

¡]¤@¡^­Y·í¤ëµL¬G¯Ê®u©Î½Ð°²3¦¸ªÌ¡A±N¨ú®ø©T©w§É¦ì¤§¸ê®æ¡C
¡]¤G¡^­Y¦³Âà°|©Î¥X°ê®È¹CªÌ¡A¥i¦V¤u§@¤H­û¯Á¨ú³zªRÂà¶E³æ¡C
¡]¤T¡^©T©w§É¦ìªÌ¥¼±a´Ö³QÂdÆ_°Í®É¡A¥i¦VªvÀø®v­É¤@®M´Ö³Q²Õ¡F­Y´Ö³QÂdÆ_°Í¿ò¥¢¡A§iª¾¹q¸£«Ç³B²z¡C

¤C¡B·í¤é³zªRµÇ¤Í¡A¥i«ù¨T¨®¡B¾÷¨®°±¨®ÃÒ¡qºÏ¦©¡r¥æ¥ÑªvÀø®v¡A©Î½Ð°Æ²Õªø»\§K¶O°±¨®³¹¡A¨Ãµù©ú¯f¤H©m¦W¤Î¨®¸¹§Y¥i§K¶O°±¨®¡C

¤K¡BªÀ·|ºÖ§Q¸ê°T¡G
¥Ó½Ð­«¤j¶Ë¯fÃÒ©ú¥d¤Î´Ý»Ù¤â¥U¡C¦p§C¦¬¤J¥Í¬¡¸É§U¡B©~®aªA°È·ÓÅU¡B¥þ¥Á°·±d«OÀI¶O¸É§U¡B»²§U¾¹¨ã¸É§U¡B´N¾Ç¶O¥Î´î§K¡B´N·~«O»Ù¡B¨T¨®µP·Óµ|´î§Kµ¥±¹¬I¡C

¤E¡B¹q¸£¶i¤J°]¹Îªk¤Hªø©°¬ö©ÀÂå°|¥þ²y¸ê°Tºôºô¯¸¡÷ÂåÀøªA°È¡÷½Ã±Ð¶é¦a·j´M¬ÛÃö½Ã±Ð¸ê®Æ¡CÅwªï±z»P¬~µÇ«ÇÁpµ¸¡C
 
*¦³¤@¨Ç°w¾¯¤Î«DµÇŦ¬ì¥ÎÃÄ¡A»Ý¦Û¦æ±¾¶E®³ÃÄ¡C ƒå
*¥»³æ¦ì¤u§@¤H­û¤§¤u§@¯Z§O±Ä¤T¯Z½ü´À­Ý¤£©w´Á¥ð°²¨î¡A²{³õ¯f¤H·ÓÅ@­ì«h¤D¦b¦¹½ü¯Z¥ð°²¨î«×¤U¾¨¶q¬I¦æ²{³õ·ÓÅ@¡C ƒå
*¦³¥ô¦ó¤£²M·¡¨Æ¶µ¥²¶·¬¢¸ß²{³õ¤u§@¤H­û¡A°ò©ó¯f¤H¦w¥þ¤Î³d¥ôÂç²M¦Ò¶q¡A¸T¤îµÇ¤Í»P®aÄݾާ@ÂåÀø³]³Æ¤Î»ö¾¹¡C ƒå
*·í§É³æ¡BªEÀY®M¡BªEÀY¡B´Ö³Q®M¤Î´£³Uµ¥¿ò¥¢©Î¯}·l¡A¶È¤©§ó´«¤w²M¬~¹L


¦å²G³zªR¶¼­¹­ì«h

¤@¡B ¨¬°÷ªº¼ö¶qÄá¨ú¡G¦]¯e¯f¥»¨­ªº¦X¨Ö¯g©Î³zªR¹Lµ{¤¤§Ö³t²¾°£Å餺¦h¾lªº¤ô¤À»P§¿¬r¯À¡A±wªÌ±`±`¨­¨ü¨­Åé¯gª¬§xÂZ¡A¦p¯h­Â¡B¨ýı»Ùê¡B­¹¼¤¤£®¶¡BµÇ©Ê³h¦å¡B³J¥Õ½è¼ö¶qÀç¾i¤£¨}µ¥[1]¡CÀç¾i¤£¨}·|¥[­«¯f¤Hªº¿©¯f²v¤Î¦º¤`²v[2]¡A¦å²G³zªR±wªÌ¨C¤é«Øij¼ö¶q¨C¤½¤ç²z·QÅé­«35¤j¥d[3]¡C
¤G¡B ¨¬°÷³J¥Õ½èÄá¨ú¡G¶i¦æ³zªRªº¯f¤H¡A¨C¤p®É¬ù¬y¥¢1¤½§Jªº³J¥Õ½è¡A¬GÀ³¼W¥[³J¥Õ½èÄá¨ú¶q[3]¡A³J¥Õ½è¨C¤Ñ«ØijÄá¨ú¨C¤½¤çÅé­«1.2-1.3§J[4]¡A¨ä¤¤¥²¶·¦³1/2-2/3¥H¤W¨Ó¦Û©óÀu½è¤§³J¥Õ½è¡A¦p¡G³½¡B¦×Ãþ¡B¶À¨§»s«~(¨§¼ß¡B¨§°®¡B¨§»Gµ¥)¡BÂû³J[5]¡C
¤T¡B ±±¨î¤ô¥÷[6]¡G­YÄá¨ú¹L¦h¤ô¥÷·|³y¦¨¨­Åé¯B¸~¡A³zªR¤¤©ö§C¦åÀ£¡B¯h­Â¡B­¹¼¤¤£®¶¡B¬Æ¦Ü¤ßªÍ¿n¤ô¡A¦]¦¹¨C¤G¦¸³zªR¶¡ªºÅé­«¼W¥[¡A¤£¥i¶W¹L°®Åé­«ªº3-5% (¬ù1.5-2¤½¤ç)¡C ¥i¯d·N¥H¤U´XÂI­ì«h¡G
(1) ª`·N¨C¤ÑÅé­«ÅܤơC
(2) ¤F¸Ñ´I§t¤ô¥÷ªº­¹ª«¨Ó·½¡A¦p¡G¤ôªG¡B¶¼®Æ¡B´ö¡Bµ}¶ºµ¥¡C
(3) ¨C¤é«Øij¶¼¤ô¶q¡G§¿²G±Æ¥X¶q+500~700c.c¡A¨Ã©w´Á¶q´ú§¿¶q¡C
(4) ¾Ç²ß±N¤@¤é¶¼¥Î¤ô¶q¥H©T©w®e¾¹¸Ë¦n¡A¤À°t¶¼¥Î¡C
¥|¡B ­­¨îÁC¶¼­¹­ì«h[5, 7]¡G
1. ÁC´¶¹M¦s¦b©Ò¦³§t³J¥Õ½èªº­¹ª«¤¤¡A¶¼­¹°£¤F­nÁקKÄá¨ú°ªÁC­¹ª«¡AÁÙ¯àÂǥѪA¥ÎÁCªºµ²¦X¾¯(¦pºÒ»Ä¶t©Î¾L»Ä¶t)¨Óí©w¡A¦]¦¹¦Y¥¿À\¡AÂI¤ß©Î¦³³Ü¤û¥¤®É¡A°O±o»P­¹ª«¤@°_§¡¤ÃªA¥Î¡C
2. ´î¤Ö°ªÁC­¹ª«Äá¨ú¡G
(1) ¨Å»s«~¡G¤û¥¤¡B¥¤¯»¡B¦Ï¥¤¡BÀu¹T¨Å¡B¨Å¹T¡BÀu®æµ¥¡C
(2) °®¨§Ãþ¡G¬õ¨§¡Bºñ¨§¡BÅú¨§¡B¤ò¨§¡B«C¨§¤¯µ¥¡C
(3) ¥þ½\Ãþ¡G¤­½\¯»(¦Ì)¡BÁW¦Ì¡B½¬¤l¡Bíõ¤¯¡B¿P³Á»P¨ä»s«~¦pÂø³ÄÑ¥]¡C
(4) °íªGÃþ¡Gªá¥Í¡B¥Ê¤l¡B¸yªG¡B®Ö®ç¡B¶}¤ßªG¡BªÛ³Âµ¥¡C
(5) ¨ä¥L¡G³J¶À¡BÂû³J¨§»G¡B¤ºÅ¦Ãþ(½Þ¨x¡B½Þ¤ßµ¥)¡B±a°©¦Yªº³½Ãþ(§k¥J³½¡B¬h¸­³½)¡B¥[¤u¤ÎÅøÀY­¹«~(¤õÁç¤YÃþ¡B¤õ»Lµ¥)¡B¥i¥i¡B¥i¼Ö¡B§ZÁC¯×¡C
¤­¡B ­­¨î¹[¶¼­¹­ì«h[5, 8]¡G
1. ³z¹L²i½Õ¤è¦¡´î¤Ö­¹ª«ªº¹[§t¶q¡G¦]¹[Â÷¤l©ö·»©ó¤ô¡A¥B´¶¹M¦s©ó¦UÃþ­¹ª«¡A¦]¦¹¥i±N­¹ª«¤Á¤p¬q¥Îºu¤ô¿S¹L¼´°_¡A¦A¥Hªoª£©Îªo©Õ¡C
2. ´î¤Ö°ª¹[­¹ª«Äá¨ú¡G
(1) °ª´öÃþ­¹ª«¡Gµæ´ö¡B³½´öµ¥¡C
(2) °®Àê½­ªGÃþ¤ÎªG¥Ä¡G¸²µå°®¡B²æ¤ô¤ôªG¡B°¨¹aÁ¦¤ù¡B¬h¾í¥Ä¡B®á߸¥Äµ¥¡C
(3) ¥Í­¹¡G¥Íµæ¨F©Ô¡B¥Í³½¤ùÃþ¡Bºë¤O´ö¡C
(4) ©Ò¦³¥¤Ãþ¤Î¨ä»s«~¡GÂA¥¤¡B¥¤¯»¡BÀu®æ¡B¨Å¹Tµ¥¡C
(5) °íªGÃþ¡Gªá¥Í¡B¥Ê¤l¡B®Ö®ç¡B§ö¤¯ªGµ¥¡C
(6) ¤¤¯óÃÄ¡B«C¯ó¯ù¡BÂûºë¡B¹B°Ê¶¼®Æ¡B¤Hçx´öµ¥¡C
(7) ¾A«×Äá¨ú°ª¹[¤ôªG¡G¥ÊÃþ¤ôªG¡B¤pµf­X¡B¯ó²ù¡B©_²§ªG¡B®ç¤lµ¥¡A¤@¤Ñ¤Å¶W¹L2¤p¸J¡C
¤»¡B §CÆQ¶¼­¹­ì«h[5, 9]¡G
1. °ªÆQ¤Àªº­¹ª«·|³y¦¨º¯³z©Êªº¤f´÷·P¦Ó¼W¥[¤ô¤ÀªºÄá¨ú¡A¤]¤£§Q©ó¦åÀ£ªº±±¨î¡C¦]¦¹¡A­¹ª«¿ï¾Ü¤W¥H¤ÑµM­¹ª«¬°¥D¡AÁקK­«¤f¨ýªº²i½Õ¡A¾i¦¨²M²H¶¼­¹²ßºD¡C
2. ÁקK§tÆQ¤À°ªªº­¹ª«¡G
(1) ¥[¤u¦×«~¡G¤õ»L¡B­»¸z¡BÂtÂû¡B³½°®¡B¥Ö³J¡BÄгJµ¥¡C
(2) ÅøÀY»s«~¡GÂæ¥Ê¡BÄѵ¬¡B¨§»G¨Å¡BÄJ³½¡BÂC³½¡C
(3) ½Õ¨ý®Æ¡G¨F¯ùÂæ¡Bµf­XÂæ¡BÂæªo»I¡B¨ýäø¡C
(4) ¾M»s½­ªG¡Gº^µæ¡BÂæµæ¡Bªwµæ¡B³·¸Ì¬õ¡B±ö°®µæ¡B»eÀ^¡B¸Ü±öµ¥¡C
(5) ¥[ÆQ§N­á½­µæ¡G¤T¦â¨§¡B«C¨§¤¯¡C
(6) ¨ä¥L¡GÄѽu¡BªoÄÑ¡B³t­¹ÄÑ¡BĬ¥´»æ°®¡C
¤C¡B ¤£¥i­¹¥Î·¨®ç¤Î¨ä»s«~¡G¹ïµÇŦ¯f±wªÌ§t¥¼©úªº¯«¸g¬r¯À¡A«Ü¦h±wªÌ­¹¥Î«á·|µo¥ÍÄY­«¥´ÜÐ[5]¡C
¡ã°ª¶¯ªø©°Àç¾iªvÀø¬ìÃö¤ß±z¡ã

 

½²ªöªY¡AÀç¾i¬ì¡A¤å³¹¨Ó·½¡G
1.Hagren, B., et al., Maintenance haemodialysis: patients’ experiences of their life situation.Journal of clinical nursing, 2005. 14(3): p. 294-300.
2.dialysis, A.o. and n.i.c.p.d.a.w.c. outcomes, Canada-USA (CANUSA) Peritoneal Dialysis Study Group.J Am Soc Nephrol, 1996. 7(2): p. 198-207.
3.¾G¥ü§g¡B¶À²Q«W¡B¤B«a¥É¡B§d²Q¦p¡B¸­Ä_µØ¡BÁé²Q­^¡B±i¤ëµÓ¡BÀ¹Þ±¡B¸â¥òµÎ¡B¶À¨q¯]¡B¤Õ¼y»D¡B¿½¤d¯§, ¹ê¥Î¿¯­¹Àø¾i¾Ç²Ä¤»ª©. 2017.
4.¬x²À²Nand ¼B­»Äõ, º¥¶i¦¡¦å²G³zªR»P³J¥Õ½èÀç¾i»Ý¨D.µÇŦ»P³zªR, 2018. 30(2): p. 97-100.
5.½Ã¥ÍºÖ§Q³¡°ê¥Á°·±d¸p¡B°ª¶¯Âå¾Ç¤j¾Çªþ³]¤¤©M¬ö©ÀÂå°|µÇŦ·ÓÅ@¹Î¶¤¡B¥xÆWµÇŦÂå¾Ç·|, ºC©ÊµÇŦ¯f°·±dºÞ²z¤â¥U. 2018.
6.§d¬õ½¬, ³zªR¯f¤H´Ý¾lµÇ¥\¯à¤§­«­n©Ê-±±¨î¶¼­¹ªºÆQ¤À¤Î¤ô¤À¤§À³¥Î.µÇŦ»P³zªR, 2015. 27(2): p. 98-102.
7.§d¬õ½¬, et al., ºC©ÊµÇŦ¯f±±¨î°ª¦åÁCªº¶¼­¹ª¾ÃÑ»P½Ã±Ð§Þ¥©.µÇŦ»P³zªR, 2010. 22(3): p. 206-209.
8.§d¬õ½¬, ¦å²G³zªR¯f¤H±±¨î¦å¹[ªº­«­n©Ê-¶¼­¹µ¦²¤.µÇŦ»P³zªR, 2016. 28(4): p. 155-159.
9.Eknoyan, G., et al., KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease.Kidney Int, 2013. 3(1): p. 5-14.¡A2019/02/12§ó·s


¦åºÞ³q¸ô±M°Ï

(1)ªø´Á©Ê³zªR¾ÉºÞ©~®a·ÓÅ@½Ã±Ð

½²¿·Áé¡B¤ý¬K¸­¡B¶À´f«i¡B¶À¼e¦p¡AµÇŦ¬ì¦å²G³zªR«Ç¡B¤å³¹¨Ó·½¡G
1.Astle CM. (2007). Hemodialysis catheter exit site care. Contrib Nephrol. 2007;154:84-96.
2.¤ý´Ó½Î¡BªL§Ó¼y ¡B·¨¤­±` ¡B¾¤«ä·½¡]2015¡^¡E³zªR¾ÉºÞ¥\¯à¤£¨}»P«D¶Ç²Î³zªR¾ÉºÞ¡EµÇŦ»P³zªR¡A27 (1)¡A28-32¡C
3.¥xÆW¦å²G³zªR¶EÀø«ü¤Þ (2004)¡E«ü¤Þ ¢º5: ¼È®É©Ê¦åºÞ³q¸ô-ÂùµÄÀR¯ß¾ÉºÞ (P.23-27)¡E¥xÆWµÇŦÂå¾Ç·|½sµÛ¡A2019/02/12§ó·s


»{ÃÑB«¬»PC«¬¨xª¢

©Ò¿×¨xª¢¬O¨x¨ü¨ì¯f¬r¡BÃĪ«¡B°sºë¡B¤Æ¾Çª««~µ¥¶Ë®`³y¦¨ªº¶Ë®`¤ÏÀ³¡A¥xÆW¦a°Ïªº«æºC©Ê¨xª¢¤¤¡A¥HB«¬¨xª¢¯f¬r·P¬V¬°³Ì¦h¡F¦b¥xÆW¦å²G³zªR±wªÌB«¬¨xª¢¤ÎC«¬¨xª¢¶§©Ê²±¦æ²v¥k¬ù¦û12-15%¡A¦Ó¨C¦~¦]¨x¯f¦º¤`ªº¤ñ¨Ò¤j¬ù¬O³zªR¯f±wªº0.15%¡A¥Bµo¥Í¨xÀù¤ñ¨Ò¸û¥¿±`¤H°ª¡A©Ò¥H¯f¬r©Ê¨xª¢ªº¨¾ªv¡A¹ê¤£®e©¿µø¡C
¤G¡B¶Ç¬V³~®|»P¯gª¬

 

¯f¬r

·P¬V³~®|

¯gª¬

B¨x

DNA¯f¬r

1.¶g²£´Á·P¬V
2.¿é¦å©Î¦å²G»s«~
3.ÃĪ«ÀݥΤΦ@¦PÀR¯ßª`®g¾¹¨ã
4.°w¤ã©Î¶Ë¤f·P¬V
5.¨ë«C¡B¯¾¬Ü¡B¬ï¦Õ¬}
6.©Ê±µÄ²

1.ºC©ÊB«¬¨xª¢¡G¤j³¡¤À¯f±w¨S¦³¯gª¬
2.«æ©ÊB«¬¨xª¢¡G­Â«å¡B¹½­¹¡B¶À¯n¡B¯ù¦â§¿¡C

C¨x

RNA¯f¬r

1.¿é¦å©Î¦å²G»s«~
2.ÃĪ«ÀݥΤΦ@¦PÀR¯ßª`®g¾¹¨ã
3.°w¤ã©Î¶Ë¤f·P¬V
4.¨ë«C¡B¯¾¬Ü¡B¬ï¦Õ¬}
5.©Ê±µÄ²

·P¬V¤FC«¬¨xª¢¯f¬r«á¡A·|¾ú¸g2¶g¦Ü¥b¦~®É¶¡ªøµu¤£µ¥ªº¼ç¥ñ´Á¡A¦Ó¥i¯àµo¥Í«æ©Ê¨xª¢¡A¥B¦¹®É¸û¤Ö¥X²{¤£¾A¯gª¬¡A©Ò¥H¤£®e©ö³Q±wªÌ¹îı¡C

¤T¡Bª`·N¨Æ¶µ¡G

    1. ¶¼­¹¡G¼ö¶q»Ý¨¬°÷¡AÀ³ÁקK³Ü°s¤Î¦Yªo¬µªº­¹ª«¡C
    2. ÃĪ«¡G¤Å¶ÃªA¥Î¦¨¥÷¤£©ú¤§ÃĪ«¡C
    3. ¿é¦å¡G¤Å±µ¨ü¤£¥²­nªº¿é¦å»Pª`®g¡C
    4. ¹jÂ÷¡G¥­®ÉÀ³¾i¦¨¨}¦nªº½Ã¥Í²ßºD¨ê¤ú¡B¤ò¤y¡B«c¤Mµ¥¤£À³»P¥L¤H¦@¥Î¡C
    5. ¥Í¬¡§@®§­n¥¿±`¡A¤Å¼õ©]¡C

¥|¡B¨xª¢ªº¨¾Å@±¹¬I¡G

    1. ´î¤Ö¿é¦å¤ÎÀR¯ßÃĪ«ª`®gªºÀݥΡC
    2. µ¹¤©¤À°ÏªvÀø¡C
    3. ªvÀø°Ï±µÄ²ÂåÀø¥Îª«¶Ô¬~¤â¡A¤Å¦b³zªRªvÀø°Ï¶i­¹¡AÁקK³y¦¨¥æ¤¬·P¬V¡C
    4. ¸gÀËÅçÃÒ¹êºC©Ê¨xª¢¶§©Ê¤§¯f±w¡A¨C¥b¦~¦Ü¤@¦~»Ý©w´Áªù¶E°lÂÜ¡A¨C¤ë¨Ò¦æÀËÅç¦p¦³²§±`°¾°ª®É¡A«Øij¦Ü¨xÁx¬ìªù¶E°lÂÜ¡C

°Ñ¦Ò¤åÄm

  1. °ª¹Å§»(2012) ¡DB «¬¨xª¢±wªÌ¤é±`¥Í¬¡«Øij¡D°·±d¥@¬É¡A320¡A25-29¡C
  2. ½Ã¥ÍºÖ§Q³¡¯e¯fºÞ¨î¸p(2018) ¡D«æ©Ê¯f¬r©Ê B «¬¨xª¢¡D¨ú¦Û http://www.cdc.gov.tw/diseaseinfo.aspx?treeid=8D54C504E820735B&nowtreeid =DEC84A2F0C6FAC5B&tid=5CA41646EE28F677.
  3. ½Ã¥ÍºÖ§Q³¡¯e¯fºÞ¨î¸p(2018) «æ©Ê¯f¬r©Ê¢Ñ«¬¨xª¢ . ¨ú¦Ûhttps://www.cdc.gov.tw/professional/submenu.aspx?treeid=ac81be2a11a0fcef&nowtreeid=4a8c72924286cab0
  4. ²ºa«n¡]2012¡^¡DºC©Ê B «¬¨xª¢ªvÀøªº²{ªp¡D¤º¬ì¾Ç»x¡A23¡]6¡^¡A377-382¡C
°ª¶¯¦å²G³zªR«Ç   2019.02.10

 


ºC©ÊµÇŦ¯f¶¼­¹­ì«h

¤@¡B ¨¬°÷ªº¼ö¶qÄá¨ú¡G±wªÌ±`¦]¶¼­¹­­¨î¹LÄY©Î¯e¯f´c¤Æ²£¥Í¹½­¹¡AÄ~¦Ó³y¦¨¼ö¶qÄá¨ú¤£¨¬¡A¤Þ°_³J¥Õ½è¼ö¶q¯Ó·l²{¶H¡A¥[³tµÇ¥\¯à´c¤Æ[1]¡C¬ü°êKDOQI«ü¤Þªº«Øij¼ö¶q¡A¤p©ó60·³¯f¤H¨C¤ÑÀ³Äá¨ú¨C¤½¤çÅé­«35¤j¥d¡A¤j©ó60·³¯f¤HÄá¨ú¨C¤½¤çÅé­«¦b30-35¤j
¤G¡B ±Ä¨ú§C³J¥Õ¶¼­¹¡G±±¨î¶¼­¹¤¤³J¥Õ½èÄá¨ú¡A¥i¥H´î¤Ö§t´á¼oª«ªº²£¥Í¡A©µ½w§¿¬r¯gª¬¡AºC©ÊµÇŦ¯f±wªÌ³J¥Õ½èÄá¨ú¨C¤Ñ¨C¤½¤çÅé­«0.6-0.8§J[3]¡C¦b­­¨î³J¥Õ½è¤U¡A¥²¶·¦³1/2-2/3¥H¤W¨Ó¦Û©óÀu½è¤§³J¥Õ½è¡A¦p¡G³½¡B¦×Ãþ¡B¶À¨§»s«~(¨§¼ß¡B¨§°®¡B¨§»Gµ¥)¡BÂû³J[4]¡C
¤T¡B ¸É¥R¨¬°÷ªº§C³J¥Õ¼ö¶q­¹«~[4]¡G
(1) §C´á¾ý¯»Ãþ¡G¥V¯»¡BﻡB¦è¨¦¦Ì¡B¯»¨¤µ¥¡C
(2) ºë»s¿}¡G¬â¿}¡BªG¿}¡B¦B¿}¡B¸Á»eµ¥¡A¦ý¦³¦å¿}±±¨î¤£¨Î±¡ªp®É¡A«Øij§ï¨Ï¥Î¥N¿}[5]¡C
(3) ¸²µå¿}»E¦Xª«¡G¿}¹~¡B¯»¹~¡B³ÁªÞ½kºë¡C
(4) ªo¯×Ãþ¡G´Óª«ªo©Î½Õ©Mªoµ¥¡AÁקK¤Ï¦¡¯×ªÕÄá¨ú[1]¡C

¥|¡B ­­¨îÁC¶¼­¹­ì«h[4, 6]¡G
1. ÁC´¶¹M¦s¦b©Ò¦³§t³J¥Õ½èªº­¹ª«¤¤¡A¶¼­¹°£¤F­nÁקKÄá¨ú°ªÁC­¹ª«¡AÁÙ¯àÂǥѪA¥ÎÁCªºµ²¦X¾¯(¦pºÒ»Ä¶t©Î¾L»Ä¶t)¨Óí©w¡A¦]¦¹¦Y¥¿À\¡AÂI¤ß©Î¦³³Ü¤û¥¤®É¡A°O±o»P­¹ª«¤@°_§¡¤ÃªA¥Î¡C
2. ´î¤Ö°ªÁC­¹ª«Äá¨ú¡G
(1) ¨Å»s«~¡G¤û¥¤¡B¥¤¯»¡B¦Ï¥¤¡BÀu¹T¨Å¡B¨Å¹T¡BÀu®æµ¥¡C
(2) °®¨§Ãþ¡G¬õ¨§¡Bºñ¨§¡BÅú¨§¡B¤ò¨§¡B«C¨§¤¯µ¥¡C
(3) ¥þ½\Ãþ¡G¤­½\¯»(¦Ì)¡BÁW¦Ì¡B½¬¤l¡Bíõ¤¯¡B¿P³Á»P¨ä»s«~¦pÂø³ÄÑ¥]¡C
(4) °íªGÃþ¡Gªá¥Í¡B¥Ê¤l¡B¸yªG¡B®Ö®ç¡B¶}¤ßªG¡BªÛ³Âµ¥¡C
(5) ¨ä¥L¡G³J¶À¡BÂû³J¨§»G¡B¤ºÅ¦Ãþ(½Þ¨x¡B½Þ¤ßµ¥)¡B±a°©¦Yªº³½Ãþ(§k¥J³½¡B¬h¸­³½)¡B¥[¤u¤ÎÅøÀY­¹«~(¤õÁç¤YÃþ¡B¤õ»Lµ¥)¡B¥i¥i¡B¥i¼Ö¡B§ZÁC¯×¡C
¤­¡B ­­¨î¹[¶¼­¹­ì«h[4, 7]¡G
1. ³z¹L²i½Õ¤è¦¡´î¤Ö­¹ª«ªº¹[§t¶q¡G¦]¹[Â÷¤l©ö·»©ó¤ô¡A¥B´¶¹M¦s©ó¦UÃþ­¹ª«¡A¦]¦¹¥i±N­¹ª«¤Á¤p¬q¥Îºu¤ô¿S¹L¼´°_¡A¦A¥Hªoª£©Îªo©Õ¡C
2. ´î¤Ö°ª¹[­¹ª«Äá¨ú¡G
(1) °ª´öÃþ­¹ª«¡Gµæ´ö¡B³½´öµ¥¡C
(2) °®Àê½­ªGÃþ¤ÎªG¥Ä¡G¸²µå°®¡B²æ¤ô¤ôªG¡B°¨¹aÁ¦¤ù¡B¬h¾í¥Ä¡B®á߸¥Äµ¥¡C
(3) ¥Í­¹¡G¥Íµæ¨F©Ô¡B¥Í³½¤ùÃþ¡Bºë¤O´ö¡C
(4) ©Ò¦³¥¤Ãþ¤Î¨ä»s«~¡GÂA¥¤¡B¥¤¯»¡BÀu®æ¡B¨Å¹Tµ¥¡C
(5) °íªGÃþ¡Gªá¥Í¡B¥Ê¤l¡B®Ö®ç¡B§ö¤¯ªGµ¥¡C
(6) ¤¤¯óÃÄ¡B«C¯ó¯ù¡BÂûºë¡B¹B°Ê¶¼®Æ¡B¤Hçx´öµ¥¡C
(7) ¾A«×Äá¨ú°ª¹[¤ôªG¡G¥ÊÃþ¤ôªG¡B¤pµf­X¡B¯ó²ù¡B©_²§ªG¡B®ç¤lµ¥¡A¤@¤Ñ¤Å¶W¹L2¤p¸J¡C
¤»¡B §CÆQ¶¼­¹­ì«h[4, 8]¡G
1. ­¹ª«¿ï¾Ü¤W¥H¤ÑµM­¹ª«¬°¥D¡AÁקK­«¤f¨ýªº²i½Õ¡A¾i¦¨²M²H¶¼­¹²ßºD¡C
2. ÁקK§tÆQ¤À°ªªº­¹ª«¡G
(1) ¥[¤u¦×«~¡G¤õ»L¡B­»¸z¡BÂtÂû¡B³½°®¡B¥Ö³J¡BÄгJµ¥¡C
(2) ÅøÀY»s«~¡GÂæ¥Ê¡BÄѵ¬¡B¨§»G¨Å¡BÄJ³½¡BÂC³½¡C
(3) ½Õ¨ý®Æ¡G¨F¯ùÂæ¡Bµf­XÂæ¡BÂæªo»I¡B¨ýäø¡C
(4) ¾M»s½­ªG¡Gº^µæ¡BÂæµæ¡Bªwµæ¡B³·¸Ì¬õ¡B±ö°®µæ¡B»eÀ^¡B¸Ü±öµ¥¡C
(5) ¥[ÆQ§N­á½­µæ¡G¤T¦â¨§¡B«C¨§¤¯¡C
(6) ¨ä¥L¡GÄѽu¡BªoÄÑ¡B³t­¹ÄÑ¡BĬ¥´»æ°®¡C
¤C¡B ¤£¥i­¹¥Î·¨®ç¤Î¨ä»s«~¡G¹ïµÇŦ¯f±wªÌ§t¥¼©úªº¯«¸g¬r¯À¡A«Ü¦h±wªÌ­¹¥Î«á·|µo¥ÍÄY­«¥´ÜÐ[4]¡C

ªø©°Âå°|µÇŦ¬ì±M¥ôÀç¾i®v°t¦XºC©ÊµÇŦ¯fªù¶E¦@¦P¾n¶E°õ¦æ¶¼­¹«ü¾É ±wªÌ¦p¦³Àç¾i°ÝÃD¡A¬Ò¥i¦VÀç¾i®v¿Ô¸ß¡C
¡ã°ª¶¯ªø©°Àç¾iªvÀø¬ìÃö¤ß±z¡ã

 

°Ñ¦Ò¤åÄm
1. ¤ýÄRµÓ and ³¢¯À®Z, µoª¢«ü¼Æ¶qªí©óºC©ÊµÇŦ¯f¯f¤HÀç¾i¤£¨}¤§Á{§ÉÀ³¥Î.¹Å°òÅ@²z, 2016. 16(2): p. 1-9.
2. Initiative, K.D.O.Q., K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. American journal of kidney diseases: the official journal of the National Kidney Foundation, 2003. 41(4 Suppl 3): p. I.
3. °]¹Îªk¤H°ê®a½Ã¥Í¬ã¨s°|¡B¥xÆWµÇŦÂå¾Ç·|, ¥xÆWºC©ÊµÇŦ¯fÁ{§É¶EÀø«ü¤Þ±M®Ñ. 2015.
4. ½Ã¥ÍºÖ§Q³¡°ê¥Á°·±d¸p¡B°ª¶¯Âå¾Ç¤j¾Çªþ³]¤¤©M¬ö©ÀÂå°|µÇŦ·ÓÅ@¹Î¶¤¡B¥xÆWµÇŦÂå¾Ç·|, ºC©ÊµÇŦ¯f°·±dºÞ²z¤â¥U. 2018.
5. Peppa, M. and S.A. Raptis, Advanced glycation end products and cardiovascular disease. Current Diabetes Reviews, 2008. 4(2): p. 92-100.
6. §d¬õ½¬, et al., ºC©ÊµÇŦ¯f±±¨î°ª¦åÁCªº¶¼­¹ª¾ÃÑ»P½Ã±Ð§Þ¥©.µÇŦ»P³zªR, 2010. 22(3): p. 206-209.
7. §d¬õ½¬, ¦å²G³zªR¯f¤H±±¨î¦å¹[ªº­«­n©Ê-¶¼­¹µ¦²¤.µÇŦ»P³zªR, 2016. 28(4): p. 155-159.
8. Eknoyan, G., et al., KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int, 2013. 3(1): p. 5-14.


¥~Äy¬ÝÅ@½Ã±Ð¸ê®Æ (¦¿¤å¨q¡AµÇŦ¬ì¦å²G³zªR«Ç¡A¤å³¹¨Ó·½:°ªªø¦å²G³zªR¦åºÞ³q¸ô±M°Ï” ¡A 2019/2/12§ó·s)
¤¤¬î¨Î¸`,¦Y-´N¬O³o»ò²³æ (¸­©uµÓ¡A¦å²G³zªR«Ç¡A¤å³¹¨Ó·½¡G½Ã¥ÍºÖ§Q³¡­¹«~ÃĪ«ºÞ²z¸phttp://www.fda.gov.tw¡A2019/2/12§ó·s)
¦å¹[±±¨î±M°Ï (¸­©uµÓ¡B³¢²Q«a¡B«\ÀR»ö¡AµÇŦ¬ì¦å²G³zªR«Ç ; §õ¤¯»ñ¡AÀç¾i¬ì¡A¤å³¹¨Ó·½¡G1.Á{§ÉÀç¾i¤u§@¤â¥U2.½Ã¥ÍºÖ§Q³¡»OÆW¦a°Ï­¹«~Àç¾i¦¨¤À¸ê®Æ®w3.¹Ï¤ù¨Ó·½:LINE³q°T³nÅé¡AµØ¤H°·±dºô¡AYahoo©_¼¯¹Ï¤ùÀÉ¡AGoogle¹Ï¤ùÀÉ¡B¤åÄm¨Ì¾Ú¡G½Ã¥ÍºÖ§Q³¡»OÆW¦a°Ï­¹«~Àç¾i¦¨¤À¸ê®Æ®w¡A2017/10 /09»s§@¡A2019/02/12§ó·s)
Á¤¤ß¤ñ¤ß-­°§C³zªRὺޯkµh±M°Ï (³Å±R»Ê¡B½²³Í¦|¡B³\¦Ê¼y¡BĬ²Qªâ¡B³¢²Q«a¡B³¯¼b»T¡B§õ¨Î¿Î¡B¤B¤Z´Ñ¡B§õ§°«C¡B±i©úªÚ¡BªL©ÉÄÉ¡B¹ù«º¶M¡B³\ÌÉ´º¡B¿à°¶´@¡B¿à«º¨q ¡AµÇŦ¬ì¦å²G³zªR«Ç¡B½²©ú¿Î¡A¤¤Â峡¡A¤å³¹¨Ó·½¡G2022¦~°ê®aÂåÀø«~½è¼úNHQA¥DÃD§ïµ½²Õ¤ñÁÉ2022/05/30)